English
Back
Download
Log in to access Online Inquiry
Back to the Top

EPS 0.2

$Exelixis (EXEL.US)$ that will beat expectation -0.03 to 0.23, but limited growth.
fda decision day Nov 4. Control you holding size. Could see a gap down (purely buyable), I’ll only buy as early as Friday.


update. Pro: good company, good sales growth and promising pipeline.
Con: Rude and boring conference cal… Our EPS is not big because they issued a lot of stock and option compensation.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
6
+0
3
Translate
Report
26K Views
Comment
Sign in to post a comment
个人投资观点。没有FINRA执照,不代表供职的机构或客户(反正我看不到)。不提供投资建议。临时改个名,免得被citadel找麻烦
286
Followers
20
Following
1987
Visitors
Follow